Advanced BioPhotonics enters trial agreement with Beth Israel Deaconess:
This article was originally published in Clinica
Executive Summary
Imaging firm Advanced BioPhotonics has entered into a pilot research agreement with the Beth Israel Deaconess Medical Center (BIDMC) - a teaching hospital of Harvard Medical School. As part of the agreement, BIDMC will be carrying out a clinical trial of the company's patented BioScanIR system, which it says provides a fast, noninvasive, radiation-free method for detecting diseases that affect perfusion and reperfusion in human tissue. The first phase of the trial is scheduled to begin in September 2007, said the Bohemia, New York-based company. The BioScanIR system uses the firm's proprietary DIRI - dynamic infrared imaging - technology, which has been developed for detecting and assessing pigmented lesions of the skin including melanoma and other forms of skin cancer.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.